|
|
Volumn 16, Issue 4, 2015, Pages 353-356
|
|
Conditional approval: Japan lowers the bar for regenerative medicine products
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACT;
CLINICAL TRIAL (TOPIC);
ECONOMIC ASPECT;
GOVERNMENT;
HEALTH CARE POLICY;
HEALTH INSURANCE;
HUMAN;
JAPAN;
MARKET;
MEDICAL ETHICS;
MEDICAL SOCIETY;
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
PRODUCT DEVELOPMENT;
PUBLIC-PRIVATE PARTNERSHIP;
REGENERATIVE MEDICINE;
REGISTRATION;
REIMBURSEMENT;
REVIEW;
RISK BENEFIT ANALYSIS;
SAFETY;
SOMATIC CELL;
STEM CELL TRANSPLANTATION;
DEVICE APPROVAL;
DRUG APPROVAL;
ECONOMICS;
HEALTH CARE COST;
LEGISLATION AND JURISPRUDENCE;
POSTMARKETING SURVEILLANCE;
TRANSPLANTATION;
CLINICAL TRIALS AS TOPIC;
DEVICE APPROVAL;
DRUG APPROVAL;
HEALTH CARE SECTOR;
HUMANS;
INSURANCE, HEALTH, REIMBURSEMENT;
JAPAN;
PLURIPOTENT STEM CELLS;
PRODUCT SURVEILLANCE, POSTMARKETING;
REGENERATIVE MEDICINE;
STEM CELL TRANSPLANTATION;
|
|
EID: 84926211549
PISSN: 19345909
EISSN: 18759777
Source Type: Journal
DOI: 10.1016/j.stem.2015.03.013 Document Type: Note |
|
Times cited : (56)
|
|
References (9)
|
